Table 2.
Antibody titer half-lives.
| Half-life (day) of antibody titer (95%CI) |
|||
|---|---|---|---|
| Severity | After peak titer | After 30 days post-onset* | |
| RBD-IgG | Mild | 56.6 (33.1–194.3) | 2804 (67.7– −71.2) |
| Moderate | 34.5 (24.9–55.9) | 101.3 (32.1– −88.0) | |
| Severe | 27.7 (22.8–35.4) | 42.8 (31.8–65.2) | |
| Combined | 32.9 (27.7–40.7) | 57.9 (40.5–95.0) | |
| RBD-IgM | Mild | 23.3 (18.1–32.7) | 43.4 (23.3–315.1) |
| Moderate | 22.9 (18.2–31.1) | 40.2 (19.0– −334.0) | |
| Severe | 16.6 (14.5–19.3) | 22.7 (18.0–30.7) | |
| Combined | 19.3 (17.3–21.9) | 26.6 (21.3–35.5) | |
| Ectodomain | Mild | 41.5 (28.4–76.8) | 50.0 (24.4– −951.5) |
| Moderate | 63.5 (38.0–192.7) | 130.8 (29.0– −52.1) | |
| Severe | 47.0 (33.1–81.5 | 66.9 (33.9–2194) | |
| Combined | 49.3 (38.3–69.3) | 60.6 (36.4–180.0) | |
| N | Mild | 37.5 (25.2–73.2) | 29.2 (18.4–70.7) |
| Moderate | 42.1 (27.5–89.8) | 1412 (33.7– −35.7) | |
| Severe | 30.4 (23.0–44.9) | 48.5 (28.9–151.1) | |
| Combined | 35.5 (28.6–46.9) | 43.4 (29.4–83.1) | |
| Neutralization | Mild | 39.3 (23.2–126.2) | 28.8 (17.3–84.6) |
| Moderate | 36.8 (22.8–95.6) | −556.8 (33.2– −29.7) | |
| Severe | 40.7 (28.2–73.1) | 107.8 (43.6– −228.9) | |
| Combined | 39.6 (30.0–58.1) | 71.8 (39.8–369.8) | |
⁎
Negative half-lives theoretically correspond to doubling times as calculated by using the statistical model. However, they should be interpreted as “infinite” if such a reversal after peak-out is biologically unlikely.